Successful long-term ibrutinib treatment in a hemodialysis patient with leukemic non-nodal mantle cell lymphoma

Publication date: Available online 9 October 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Hajime Yasuda, Yutaka Tsukune, Tadaaki Inano, Yosuke Mori, Yasunori Ota, Norio Komatsu
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research

Related Links:

The COVID-19 pandemic has proven to have significant morbidity and mortality in high risk patient populations including those with cancer. Chronic lymphocytic leukemia (CLL) is an indolent disease and the majority of patients with CLL are under monitoring. Here we present a case of a CLL patient with severe COVID-19 presenting with marked lymphocytosis within 2-3 days of diagnosis. An 80-years old man with treatment na ïve CLL was admitted to our hospital for COVID-19 pneumonia. He was intubated due to hypoxic respiratory failure and developed multi-system organ failure requiring hemodialysis and vasopressor therapy.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Case Report Source Type: research
ConclusionChemotherapy followed by ASCT using a conditioning regimen of reduced melphalan and pharmacokinetically targeted busulfan is a promising strategy for treating patients with relapsed or refractory DLBCL who also have end-stage renal disease and are receiving hemodialysis.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 7 November 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Kaoru Morita, Masahiro Ashizawa, Yumiko Toda, Takashi Ikeda, Shin-ichiro Kawaguchi, Shoko Ito, Shin-ichi Ochi, Takashi Nagayama, Kiyomi Mashima, Kento Umino, Daisuke Minakata, Hirofumi Nakano, Ryoko Yamasaki, Chihiro Yamamoto, Kaoru Hatano, Shin-ichiro Fujiwara, Kazuya Sato, Iekuni Oh, Ken Ohmine, Kazuo MuroiAbstractAbout 40% of patients with diffuse large B cell lymphoma (DLBCL) relapse after or are refractory to standard chemotherapy with rituximab plus cyclophosphamide, hydroxydaunorubicin, vincristine, and prednis...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
A treatment strategy of salvage chemotherapy and autologous stem-cell transplantation (ASCT) in relapsed or refractory diffuse large B-cell lymphoma (DLBCL) patients receiving hemodialysis has not yet been established. We conducted a pharmacokinetic analysis in a patient with refractory DLBCL with end-stage renal disease and successfully administered adjusted dosing of salvage chemotherapies and a conditioning regimen in ASCT without any adverse events.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
A treatment strategy of salvage chemotherapy and autologous stem cell transplantation in relapsed or refractory DLBCL patients on hemodialysis has not yet been established. We conducted a pharmacokinetic analysis in a refractory DLBCL patient with end-stage renal disease, and successfully administered adjusted dosing of salvage chemotherapies and conditioning regimen in autologous stem cell transplantation without any adverse events.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
The immunomodulatory agent pomalidomide (POM) plus dexamethasone (DEX) is approved in the United States and European Union for patients with relapsed or refractory multiple myeloma (RRMM), including those with renal impairment (RI). MM-013, a phase 2, noncomparative trial (NCT02045017; EudraCT No. 2013-001903-36), has shown a benefit with POM + DEX in patients with severe RI, including those requiring hemodialysis, and moderate RI (Dimopoulos M, et al. J Clin Oncol. 2018;36:2035-2043). Here, we report the efficacy and safety of POM + DEX treatment (Tx) for ≥ 1 year.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
Publication date: Available online 30 August 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Laura Nanni, Cinzia Pellegrini, Vittorio Stefoni, Lisa Argnani, Michele Cavo, Pier Luigi Zinzani
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 30 August 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Laura Nanni, Cinzia Pellegrini, Vittorio Stefoni, Lisa Argnani, Michele Cavo, Pier Luigi Zinzani
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Brentuximab vedotin (BV), an anti-CD30-specific antibody-drug conjugate (ADC), is one of the most promising new agents employed in the treatment of peripheral T-cell lymphomas (PTCLs), in particular, systemic anaplastic large cell lymphomas (sALCL).1,2 The drug has proved to be safe and effective both as a single agent in relapsed/refractory disease and in combination with standard chemotherapy in the first-line setting.3-7
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Case Report Source Type: research
Quantification of free light chains (FLC) is important in the diagnosis of plasma cell diseases where abnormal kappa:lambda ratio infers a population of monoclonal plasma cells. The Freelite assay and N Latex assay have been validated in a non-CKD population but there is a paucity of data relating to these assays in the end stage kidney disease (ESKD) population.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
More News: Cancer & Oncology | Dialysis | Hemodialysis | Leukemia | Lymphoma | Myeloma